Ryght AI Forms Scientific Advisory Board to Advance AI-Powered Clinical Trial Technology
核心洞察
Ryght AI (搜索) announces formation of inaugural Scientific Advisory Board comprising 12 globally recognized experts in oncology, hematology, dermatology, and AI to guide clinical trial innovation.
The board will oversee development of AI Site Twin technology, which creates dynamic digital replicas of research facilities to transform site selection and trial operations.
Advisory board members emphasize the platform's potential to accelerate patient recruitment and streamline workflows, bringing therapies to market months or years ahead of schedule.
Ryght AI (搜索), a clinical trials technology company specializing in AI Site Twin technology, announced the formation of its inaugural Scientific Advisory Board (SAB) on October 7, 2025. The board comprises 12 globally recognized experts across oncology, hematology, dermatology, artificial intelligence, healthcare technology, and digital transformation who will guide the company's strategic direction as it transforms clinical trial site selection, qualification, and activation through dynamic digital replicas of research facilities.
Addressing Clinical Trial Inefficiencies Through AI Innovation
The formation of the SAB comes as the clinical research industry grapples with persistent challenges in trial feasibility and operations. "Traditional approaches to clinical trial feasibility and operations have been hampered by static, outdated data," said Chadi Nabhan, MD, MBA, Chief Medical Officer and Head of Strategy at Ryght AI (搜索), who will chair the SAB. "Our Scientific Advisory Board brings together some of the brightest minds in medicine and research. Their expertise will help us accelerate innovation, scale our research operations, and make impactful strategic decisions as we expand the reach of our technology to help patients worldwide."
The advisory board will collaborate closely with Ryght AI (搜索)'s leadership and R&D teams to guide the scaling of research and development engines, support strategic decision-making, strengthen scientific rigor across initiatives, and facilitate partnerships with academic, clinical, and research institutions.
Expert Perspectives on AI-Driven Clinical Research
Board members expressed optimism about the technology's potential to revolutionize clinical trial operations. "Tackling the challenges of modern clinical trials demands technology that can automate complexity and generate meaningful insights at speed," said Manmeet Ahluwalia, MD, MBA, Chief of Medical Oncology, Chief Scientific Officer, and Deputy Director at Baptist Health Miami Cancer Institute (搜索). "Ryght's secure, generative AI platform and global research site network are well positioned to transform clinical research, helping bring therapies to patients faster and with greater efficiency."
Razelle Kurzrock, MD, Professor and Associate Director of the Cancer Center at the Medical College of Wisconsin, highlighted the platform's operational advantages: "By leveraging Ryght's technology and network, trial sponsors can identify optimal clinical trial sites, accelerate recruitment, and streamline complex workflows of the entire trial continuum to get therapies to market months or even years ahead of target and at lower cost."
Distinguished Advisory Board Composition
The inaugural SAB includes prominent figures from leading cancer centers and research institutions:
- Manmeet Ahluwalia, MD, MBA, FASCO - Chief of Medical Oncology, Chief Scientific Officer, and Deputy Director, Baptist Health Miami Cancer Institute
- Neeraj Agarwal, MD, FASCO - Presidential Endowed Chair of Cancer Research, Huntsman Cancer Institute
- Tanios Bekaii-Saab, MD - Chairman for the Division of Hematology/Medical Oncology, Mayo Clinic
- Rafael Fonseca, MD - Chief Innovation Officer, Mayo Clinic in Arizona
- Siavash Jabbari, MD - Medical Director of Radiation Oncology, Sharp Memorial Laurel Amtower Cancer Institute and Neuro-Oncology Center
- Elias Jabbour, MD - Professor of Medicine in Department of Leukemia, MD Anderson Cancer Center
- Razelle Kurzrock, MD - Founding Director, Michels Rare Cancers Research Laboratories, Medical College of Wisconsin
- Rana McKay, MD - Associate Professor of Medicine, University of California in San Diego
- Dedee F. Murrell, MD, MA, BMBCh, FRCP - Professor and Head, Department of Dermatology, St George Hospital
- Alan Skarbnik, MD - Director, Lymphoma & CLL Program, Director Immune Effector Cell Therapeutics Program, Novant Health
- Vivek Subbiah, MD - Chief, Early-Phase Drug Development, Sarah Cannon Research Institute
- Greg Vidal, MD, PhD - Director of Clinical Research and Lead of the Breast Cancer Program, West Cancer Center and Research Institute
AI Site Twin Technology Platform
Ryght AI (搜索)'s platform centers on AI Site Twins, which are dynamic data models representing clinical research sites worldwide. This technology empowers sponsors and contract research organizations (CROs) to accelerate clinical trial study startup through faster site selection and streamlined feasibility workflows, powered by advanced generative and agentic AI. The SOC Type 2-compliant platform enhances efficiency by fostering seamless, real-time communication between sponsors, CROs, and research sites.